Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled "Biopharmaceutical CMO and CRO Market By Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026". According to Acumen Research and Consulting, the global Biopharmaceutical CMO & CRO market is expected to grow at noteworthy CAGR around 7.5 % throughout the forecast period and reach around US$ 39 billion by 2026.
The market is driven considerably by the growing interest in biological therapy for conventional drug developers. The outsourcing strategy has currently become a cost-saving strategy for small-to-medium-sized biomass manufacturers, which helps remove the need for expensive specialty equipment or recruitment and training.
The decrease in R&D productivity and higher development costs has led to high pressure for short-term profits and profit margins on biopharmaceutical producers. The Contract Manufacturing Organisations (CMOs) and contract research organizations (CRO’s) have thus created lucrative opportunities to accelerate their activities.
Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1373
Robust investment in risk capital is one of the key drivers for growth opportunities for CMOs. Venture capital funds are more trustworthy than public equity. The increased availability of life sciences venture funds will further enhance CMO growth. These CMOs and CROs, however, face competition from pharmaceutical and biotech companies’ in-house departments. Several major pharmaceutical companies like Novartis have announced that biomass production will continue in their own countries.
The biggest share in revenues was in 2018 in mammalian cell line-based bioproduction systems. Include growth of mammalian system titers and yields as responsible for this estimated share. CMOs standardize their mammalian systems, driving the segment’s revenue growth. Contract Research Service is expected to be the fastest growing segment over the projected period due to increased investments in new therapeutic research programs. The CMOs benefit greatly from the continuous growth of biological products on the market.
A number of US biopharmaceutical companies consider developing pharmaceutical products in Asian countries. The main cause of this is the growing R&D expenses at home and the presence in Asian countries of low-cost production facilities and cheap work. The key players will also build mutually beneficial alliances with other emerging CMOs in order to increase production capacity.
View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/biopharmaceutical-cmo-and-cro-market
Key Findings
In 2018, the bioproductive system based on mammalian cell lines represented the largest sales share in the market.
Plant based systems for the production of large molecules are developed and explored as an economical alternative.
Because of the wide range of services from developing the cell lines to finishing packaging, contract manufacturing services have represented the biggest market share.
Recently, the biotechnological industry is more specialized, which has led to a large portion of the biopharmaceutical CMO & CRO market for the CMO & CROs being part of the clients ‘ biological strategies.
The biopharmaceutical industry in North America is recognized as an innovation market leader, which leads to a large portion of the region.
Key Players & Strategies
Due to the presence of a large number of developed, medium to small CMOs and CROs, this market is fragmented in nature. Many market participants are held in private or form part of the portfolios of private equity firms. Some key CMOs are Boehringer Ingelheim GmbH, Lonza, Rentschler Biotechnologie GmbH, JRS Pharma (Celonic GmbH), TOYOBO Biologics, LTD, FUJIFILM Diosynth Biotechnologies U.S.A., Patheon, CMC Biologics, and WuXi Biologics.
In order for CMOs to improve the project performance and product quality their automation and innovative technologies are integrated in their plants. The interest of large molecular producers in the CMOs has thus driven them to congregate the mounting demand for biologics. Charles River Laboratories International (LC) Inc.; PRA Health Sciences; LabCorp; ICON plc.; and Parexel International Corporation are committed to offering contract research services for large molecular production. Contract research services for large molecular production.
It is observed that outsourcing services are crucial in the overcoming of business barriers. They can make footprints in foreign markets where governments regulate local jobs by domestic production. In addition to this, small companies also began to expand their non-GMP facilities as a result of the rising demand for these services.
Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases
TABLE OF CONTENT
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Biopharmaceutical CMO and CRO
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Biopharmaceutical CMO and CRO Market By Source
1.2.2.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Source (2015-2026)
1.2.2.2. Global Biopharmaceutical CMO and CRO Market Revenue Share By Source in 2017
1.2.2.3. Non-mammalian
1.2.2.4. Mammalian
1.2.3. Biopharmaceutical CMO and CRO Market By Service Type
1.2.3.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Service Type (2015-2026)
1.2.3.2. Contract Manufacturing
1.2.3.2.1. Process Development
1.2.3.2.2. Analytical & QC studies
1.2.3.2.3. Finish & Fill Operations
1.2.3.2.4. Packaging
1.2.3.3. Contract Research
1.2.3.3.1. Oncology
1.2.3.3.2. Cardiology
1.2.3.3.3. Neuroscience
1.2.3.3.4. Inflammation & Immunology
1.2.3.3.5. Others
1.2.4. Biopharmaceutical CMO and CRO Market By Product
1.2.4.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.4.2. Biosimilars
1.2.4.3. Biologics
1.2.4.4. Monoclonal Antibodies (MAbs)
1.2.4.5. Recombinant Proteins
1.2.4.6. Vaccines
1.2.4.7. Antisense, RNAi, & Molecular Therapy
1.2.4.8. Others
1.2.5. Biopharmaceutical CMO and CRO Market by Geography
1.2.5.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.1.1. Definition of Biopharmaceutical CMO and CRO
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Biopharmaceutical CMO and CRO Market By Source
1.2.2.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Source (2015-2026)
1.2.2.2. Global Biopharmaceutical CMO and CRO Market Revenue Share By Source in 2017
1.2.2.3. Non-mammalian
1.2.2.4. Mammalian
1.2.3. Biopharmaceutical CMO and CRO Market By Service Type
1.2.3.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Service Type (2015-2026)
1.2.3.2. Contract Manufacturing
1.2.3.2.1. Process Development
1.2.3.2.2. Analytical & QC studies
1.2.3.2.3. Finish & Fill Operations
1.2.3.2.4. Packaging
1.2.3.3. Contract Research
1.2.3.3.1. Oncology
1.2.3.3.2. Cardiology
1.2.3.3.3. Neuroscience
1.2.3.3.4. Inflammation & Immunology
1.2.3.3.5. Others
1.2.4. Biopharmaceutical CMO and CRO Market By Product
1.2.4.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.4.2. Biosimilars
1.2.4.3. Biologics
1.2.4.4. Monoclonal Antibodies (MAbs)
1.2.4.5. Recombinant Proteins
1.2.4.6. Vaccines
1.2.4.7. Antisense, RNAi, & Molecular Therapy
1.2.4.8. Others
1.2.5. Biopharmaceutical CMO and CRO Market by Geography
1.2.5.1. Global Biopharmaceutical CMO and CRO Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Biopharmaceutical CMO and CRO Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Biopharmaceutical CMO and CRO Major Manufacturers in 2017
CHAPTER 4. BIOPHARMACEUTICAL CMO AND CRO MARKET BY BY SOURCE
4.1. Global Biopharmaceutical CMO and CRO Revenue By Source
4.2. Non-mammalian
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Mammalian
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.2. Non-mammalian
4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
4.3. Mammalian
4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 5. BIOPHARMACEUTICAL CMO AND CRO MARKET BY SERVICE TYPE
5.1. Global Biopharmaceutical CMO and CRO Revenue By Service Type
5.2. Contract Manufacturing
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.2.3. Process Development
5.2.4. Analytical & QC studies
5.2.5. Finish & Fill Operations
5.2.6. Packaging
5.3. Contract Research
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3.3. Oncology
5.3.4. Cardiology
5.3.5. Neuroscience
5.3.6. Inflammation & Immunology
5.3.7. Others
5.2. Contract Manufacturing
5.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.2.3. Process Development
5.2.4. Analytical & QC studies
5.2.5. Finish & Fill Operations
5.2.6. Packaging
5.3. Contract Research
5.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
5.3.3. Oncology
5.3.4. Cardiology
5.3.5. Neuroscience
5.3.6. Inflammation & Immunology
5.3.7. Others
CHAPTER 6. BIOPHARMACEUTICAL CMO AND CRO MARKET BY PRODUCT
6.1. Global Biopharmaceutical CMO and CRO Revenue By Product
6.2. Biosimilars
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Biologics
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Monoclonal Antibodies (MAbs)
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Recombinant Proteins
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.6. Vaccines
6.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.7. Antisense, RNAi, & Molecular Therapy
6.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.8. Others
6.8.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.8.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.2. Biosimilars
6.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.3. Biologics
6.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.4. Monoclonal Antibodies (MAbs)
6.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.5. Recombinant Proteins
6.5.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.6. Vaccines
6.6.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.7. Antisense, RNAi, & Molecular Therapy
6.7.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.7.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
6.8. Others
6.8.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million)
6.8.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million)
CHAPTER 7. NORTH AMERICA BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
7.1. North America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
7.2. North America Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Biopharmaceutical CMO and CRO Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.2. North America Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Biopharmaceutical CMO and CRO Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
7.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
7.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 8. EUROPE BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
8.1. Europe Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
8.2. Europe Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.2. Europe Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.6.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.6.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
8.7.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
8.7.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
9.1. Asia-Pacific Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
9.2. Asia-Pacific Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.2. Asia-Pacific Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.6.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.6.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.7.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.7.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
9.8.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
9.8.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 10. LATIN AMERICA BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
10.1. Latin America Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
10.2. Latin America Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.2. Latin America Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
10.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
10.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 11. MIDDLE EAST BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
11.1. Middle East Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
11.2. Middle East Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.2. Middle East Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
11.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
11.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 12. AFRICA BIOPHARMACEUTICAL CMO AND CRO MARKET BY COUNTRY
12.1. Africa Biopharmaceutical CMO and CRO Market Revenue and Growth Rate, 2015 – 2026 ($Million)
12.2. Africa Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
12.2. Africa Biopharmaceutical CMO and CRO Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.3.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.3.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.4.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.4.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Source, 2015 – 2026 ($Million)
12.5.2. Market Revenue and Forecast By Service Type, 2015 – 2026 ($Million)
12.5.3. Market Revenue and Forecast By Product, 2015 – 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Boehringer Ingelheim GmbH
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Lonza
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Rentschler Biotechnologie GmbH
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. JRS Pharma (Celonic GmbH)
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. TOYOBO Biologics, LTD
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. FUJIFILM Diosynth Biotechnologies U.S.A.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Patheon
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. CMC Biologics
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. WuXi Biologics
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Lonza
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Rentschler Biotechnologie GmbH
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. JRS Pharma (Celonic GmbH)
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. TOYOBO Biologics, LTD
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. FUJIFILM Diosynth Biotechnologies U.S.A.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Patheon
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. CMC Biologics
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. WuXi Biologics
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
Buy this Premium Research Report@ https://www.acumenresearchandconsulting.com/buy-now/0/1373
The report is readily available and can be dispatched immediately after payment confirmation.
Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157
0 Comments
Get More Detail Study, Visit Here: https://www.acumenresearchandconsulting.com/